Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Drug Discovery

In Vitro Evaluation of Antibodies

As we know, a complete monoclonal antibody includes an antigen-binding fragment (Fab) and a fragment crystallizable region (Fc). The Fab can bind to a tumor-associated antigen, while the Fc plays an important role in metabolic pathways, as well as in IgG cellular functions.

The molecular sequence and subtype of antibodies will affect the effector functions. Such effector functions include the antibody dependent cellular cytotoxicity (ADCC) triggered by Fc binding to the FcγRIII receptor (CD16A) of NK. The Fc can also bind with serum complement molecules (C1q) to form a membrane attack complex (MAC) that triggers complement-dependent cytotoxicity (CDC). When the Fc binds with macrophage receptors—namely FcγRIII (CD16A), FcγRII (CD32A) and FcγRI (CD64)—the antibody-dependent cellular phagocytosis (ADCP) is triggered.

Download
Medicilon diamond icon.pngService
  • ADCCCDCADCPBinding/blocking experimentsAntibody endocytosisT cell activationT cell cytotoxicity
Relevant laboratories
  • MSD
  • Biacore
  • high-speed centrifuge
  • PCR
  • Multifunctional microplate reader
  • Gyrolab-xPlore
  • Automatic plate washer
  • M5
Relevant articles